G-Atorvast20 mg

G-Atorvast is indicated for the following uses:

Established / FDA-approved uses

• As an adjunct to diet, to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in patients with primary hyperlipidemia (including heterozygous familial and non-familial hypercholesterolemia) and mixed dyslipidemia.
• To reduce elevated total cholesterol and LDL-cholesterol in patients with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable, since homozygous familial hypercholesterolemia often does not respond adequately to statins alone.
• To reduce the risk of myocardial infarction, stroke, revascularization procedures, and angina in adults without established coronary heart disease who have multiple cardiovascular risk factors, and in patients with established atherosclerotic cardiovascular disease (primary and secondary prevention).
• Pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia, as an adjunct to diet, when an adequate trial of diet therapy has failed.

Guideline-supported use

• First-line lipid-lowering therapy in patients meeting guideline thresholds for atherosclerotic cardiovascular disease risk reduction, per major cardiology society guidance.

G-Atorvast is not indicated for the acute treatment of high triglyceride levels causing pancreatitis, and is not a substitute for diet, exercise, and other lifestyle measures.

Each tablet of Atorvastatin Calcium contains atorvastatin (as atorvastatin calcium) as the active ingredient. In Bangladesh, Atorvastatin Calcium is commonly available as film-coated tablets in strengths of 10 mg, 20 mg, 40 mg, and 80 mg.

G-Atorvast is a synthetic lipid-lowering agent belonging to the statin class of medicines. It works by inhibiting the enzyme HMG-CoA reductase, which is responsible for an early, rate-limiting step in the body's production of cholesterol. By reducing cholesterol synthesis in the liver, G-Atorvast lowers blood levels of total cholesterol, LDL ("bad") cholesterol, apolipoprotein B, and triglycerides, while modestly raising HDL ("good") cholesterol.

G-Atorvast is widely used for the long-term management of high cholesterol and for reducing the risk of heart attack, stroke, and other cardiovascular events in people with or at risk of atherosclerotic cardiovascular disease.

Atorvastatin Calcium is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, an early step in hepatic cholesterol biosynthesis.

By inhibiting this enzyme, Atorvastatin Calcium reduces the amount of cholesterol produced by the liver. This prompts hepatocytes to increase the number of LDL receptors on their surface, which enhances the uptake and catabolism of LDL-cholesterol from the bloodstream and reduces circulating LDL particle production. The net effect is a reduction in total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides, with a modest increase in HDL-cholesterol.

Atorvastatin Calcium is metabolized primarily by the hepatic cytochrome P450 3A4 (CYP3A4) enzyme system, and its active metabolites contribute substantially to its lipid-lowering effect. Peak plasma concentrations occur within 1 to 2 hours of oral dosing, and the drug undergoes extensive first-pass hepatic extraction (its primary site of action).

G-Atorvast tablets may be taken orally once daily, at any time of day, with or without food. Dosing should be consistent — taken at approximately the same time each day to maintain steady drug levels. Tablets should be swallowed whole with a glass of water and should not be crushed or chewed unless otherwise directed by a physician.

Avoid taking G-Atorvast with large quantities of grapefruit juice (see Interactions).

The following are well-established, clinically significant interactions with G-Atorvast:

• Strong CYP3A4 inhibitors (e.g. clarithromycin, itraconazole, ketoconazole, HIV protease inhibitors, cyclosporine): markedly increase G-Atorvast plasma concentrations and raise the risk of myopathy/rhabdomyolysis; combination is generally avoided, or G-Atorvast dose is limited/adjusted per specific drug-pair guidance.
• Gemfibrozil and other fibrates: increase the risk of myopathy and rhabdomyolysis when combined with G-Atorvast; combination should be avoided if possible or used with close monitoring at a reduced statin dose.
• Cyclosporine: significantly increases G-Atorvast exposure; concomitant use should be limited to the lowest necessary dose with close monitoring.
• Colchicine: reports of myopathy/rhabdomyolysis when combined with statins; use with caution.
• Rifampin: can substantially reduce G-Atorvast plasma concentrations if administration is separated in time, reducing efficacy; co-administration should be simultaneous if used together.
• Oral contraceptives: G-Atorvast increases plasma concentrations of norethindrone and ethinyl estradiol; this is generally not clinically significant but should be considered.
• Digoxin: G-Atorvast modestly increases digoxin plasma concentrations; monitor for digoxin toxicity with concurrent use.
• Warfarin: no clinically significant effect on prothrombin time has been established, but periodic monitoring is reasonable when therapy is initiated or changed.
• Grapefruit juice (large quantities, >1.2 L/day): can increase G-Atorvast plasma concentrations; large amounts should be avoided.

Common and serious side effects associated with G-Atorvast include:

Common (may affect more than 1 in 100 people)

• Nasopharyngitis, joint pain (arthralgia)
• Diarrhea, dyspepsia, nausea, flatulence
• Muscle pain or discomfort (myalgia)
• Headache
• Insomnia
• Elevated liver enzymes (transaminases)

Uncommon to rare but serious

• Myopathy and, rarely, rhabdomyolysis (severe muscle breakdown that can cause kidney damage) — seek prompt medical attention for unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever, dark urine, or malaise.
• Hepatotoxicity, including rare cases of liver failure.
• Hypersensitivity reactions, including angioedema and, rarely, severe skin reactions (e.g. Stevens-Johnson syndrome).
• Increased blood glucose and new-onset type 2 diabetes (a modest signal; the cardiovascular benefit generally outweighs this risk in appropriate candidates).
• Peripheral neuropathy and memory impairment/confusion (rare, generally reversible on discontinuation).

Pregnancy: G-Atorvast is contraindicated in pregnancy. Cholesterol and other products of cholesterol biosynthesis are essential for fetal development, and inhibiting HMG-CoA reductase may cause fetal harm. G-Atorvast should be discontinued as soon as pregnancy is recognized, and it should not be started or continued in women who are planning pregnancy. Women of reproductive potential should use effective contraception during treatment.

Lactation: G-Atorvast is contraindicated during breastfeeding. It is not known whether atorvastatin is excreted in human milk, but because of the potential for serious adverse effects in a nursing infant and the general recommendation to avoid statins during lactation, women who require G-Atorvast should not breastfeed and should discuss alternative feeding or treatment options with their physician.

The following precautions apply to the use of G-Atorvast:

• Myopathy and rhabdomyolysis: G-Atorvast can cause myopathy (muscle pain, tenderness, or weakness with creatine kinase elevation) and, rarely, life-threatening rhabdomyolysis with acute kidney injury. Risk is increased by advanced age, renal impairment, hypothyroidism, and concomitant use of certain interacting drugs (see Interactions). Patients should be advised to promptly report unexplained muscle symptoms; therapy should be discontinued if myopathy is diagnosed or suspected, or if markedly elevated creatine kinase levels occur.
• Hepatotoxicity: Liver enzyme abnormalities can occur. Liver function tests are recommended before starting therapy and as clinically indicated thereafter. G-Atorvast should be used with caution in patients with a history of liver disease or substantial alcohol consumption, and is contraindicated in active liver disease.
• Glycemic control: G-Atorvast is associated with modest increases in blood glucose and glycosylated hemoglobin, and an increased risk of new-onset diabetes has been reported. Blood glucose should be monitored per standard clinical practice, particularly in patients with risk factors for diabetes.
• Not for use in active liver disease or during pregnancy/breastfeeding — see Contraindications and Pregnancy and Lactation.

There is no specific antidote for G-Atorvast overdose. Symptoms of overdose are generally not well characterized but could theoretically include exaggerated pharmacologic effects. If overdose of G-Atorvast is suspected, seek immediate medical attention or contact a poison control center right away. Treatment should be supportive, based on the patient's clinical presentation, and may include general supportive measures and monitoring of liver function and, if indicated, creatine kinase levels; hemodialysis is unlikely to significantly enhance clearance of atorvastatin due to its extensive protein binding.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: No overall differences in safety or effectiveness have been observed between elderly and younger patients, but elderly patients (especially those over 65) may be at greater risk of myopathy; standard dosing is generally appropriate with attention to muscle symptoms.
• Renal impairment: No dose adjustment is required (see Dosage and Administration).
• Hepatic impairment: G-Atorvast is contraindicated in active liver disease; use with caution and close monitoring in patients with a history of liver disease (see Precautions and Warnings).
• Pediatric patients: See Pediatric Uses.
• Pregnancy and lactation: Contraindicated — see Pregnancy and Lactation.

G-Atorvast is generally used as a long-term, ongoing therapy for the management of chronic hypercholesterolemia and for cardiovascular risk reduction, rather than for a fixed short course. Treatment duration and continued need should be reassessed periodically by the prescribing physician based on lipid response, tolerability, and overall cardiovascular risk. G-Atorvast should not be stopped abruptly without medical advice, as this may lead to a rebound in cholesterol levels and loss of cardiovascular protection.

Statins (HMG-CoA reductase inhibitors)

Atorvastatin Calcium competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, thereby upregulating hepatic LDL receptors and increasing clearance of LDL-cholesterol from the blood, while also modestly lowering triglycerides and raising HDL-cholesterol.

X

G-Atorvast is approved for use in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, as an adjunct to diet, when an adequate trial of diet therapy has failed to adequately lower LDL-cholesterol. The recommended starting dose in this population is 10 mg once daily, which may be titrated up to a maximum of 20 mg once daily based on response and tolerability; doses above 20 mg have not been studied in this age group.

Safety and effectiveness of G-Atorvast in children younger than 10 years, and in prepubertal children generally, have not been established. G-Atorvast is contraindicated in pregnancy and lactation, which is relevant when treating adolescent girls of reproductive potential — effective contraception should be discussed and pregnancy avoided during treatment.